Potent tetravalent replicon vaccines against botulinum neurotoxins using DNA-based Semliki Forest virus replicon vectors

Vaccine

Volumn 31, Issue 20, 2013, Pages 2427-2432

  Yu, Yun Zhou ^a   Guo, Jin Peng ^b   An, Huai Jie ^c   Zhang, Shu Ming ^d   Wang, Shuang ^a   Yu, Wei Yuan ^a   Sun, Zhi Wei ^a  

^a BEIJING INSTITUTE OF BIOTECHNOLOGY   (China)

^b BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^c NAVY GENERAL HOSPITAL   (China)

^d NATIONAL INSTITUTES FOR FOOD AND DRUG CONTROL   (China)

Author keywords

Botulinum neurotoxin; Dual expression; Replicon vector; Tetravalent vaccine

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B; BOTULINUM TOXIN E; BOTULINUM TOXIN F; DNA VACCINE; NEUTRALIZING ANTIBODY; TETRAVALENT REPLICON VACCINE; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BOTULISM; CONTROLLED STUDY; DNA IMMUNIZATION; DNA VECTOR; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDY; FEMALE; IMMUNOGENICITY; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPLICON; SEMLIKI FOREST ALPHAVIRUS;

ANIMALS; ANTIBODIES, NEUTRALIZING; BOTULINUM TOXINS; BOTULISM; CLOSTRIDIUM BOTULINUM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENETIC VECTORS; MICE; MICE, INBRED BALB C; NEUROTOXINS; REPLICON; SEMLIKI FOREST VIRUS; VACCINES, DNA;

EID: 84877024765     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.03.046     Document Type: Article

References (38)

1. Turton K., Chaddock J.A., Acharya K.R. Botulinum and tetanus neurotoxins: structure, function and therapeutic utility. Trends Biochem Sci 2002, 27:552-558.
2. Schiavo G., Matteoli M., Montecucco C. Neurotoxins affecting neuroexocytosis. Physiol Rev 2000, 80:717-766.
3. Dembek Z.F., Smith L.A., Rusnak J.M. Botulism: cause, effects, diagnosis, clinical and laboratory identification, and treatment modalities. Disaster Med Public Health Prep 2007, 1:122-134.
4. Arnon S.S., Schechter R., Inglesby T.V., Henderson D.A., Bartlett J.G., Ascher M.S., et al. Botulinum toxin as a biological weapon. JAMA 2001, 285:1059-1070.
5. Byrne M.P., Smith L.A. Development of vaccines for prevention of botulism. Biochimie 2000, 82:955-966.
6. Middlebrook J.L. Production of vaccines against leading biowarfare toxins can utilize DNA scientific technology. Adv Drug Deliv Rev 2005, 57:1415-1423.
7. Smith L.A., Rusnak J.M. Botulinum neurotoxin vaccines: past, present, and future. Crit Rev Immunol 2007, 27:303-318.
8. Smith L.A. Botulism and vaccines for its prevention. Vaccine 2009, 27:D33-D39.
9. Clayton M.A., Clayton J.M., Brown D.R., Middlebrook J.L. Protective vaccination with a recombinant fragment of Clostridium botulinum neurotoxin serotype A expressed from a synthetic gene in Escherichia coli. Infect Immun 1995, 63:2728-2742.
10. Holley J.L., Elmore M., Mauchline M., Minton N., Titball R.W. Cloning, expression and evaluation of a recombinant sub-unit vaccine against Clostridium botulinum type F toxin. Vaccine 2000, 19:288-297.
11. Woodward L.A., Arimitsu H., Hirst R., Oguma K. Expression of Hc subunits from Clostridium botulinum type C and D and their evaluation as candidate vaccine antigens in mice. Infect Immun 2003, 71:2941-2944.
12. Tavallaie M., Chenal A., Gillet D., Pereira Y., Manich M., Gibert M., et al. Interaction between the two subdomains of the C-terminal part of the botulinum neurotoxin A is essential for the generation of protective antibodies. FEBS Lett 2004, 572:299-306.
13. Baldwin M.R., Tepp W.H., Pier C.L., Bradshaw M., Ho M., Wilson B.A., et al. Characterization of the antibody response to the receptor binding domain of botulinum neurotoxin serotypes A and E. Infect Immun 2005, 73:6998-7005.
14. Ravichandran E., Al-Saleem F.H., Ancharski D.M., Elias M.D., Singh A.K., Shamim M., et al. Trivalent vaccine against botulinum toxin serotypes A, B, and E that can be administered by the mucosal route. Infect Immun 2007, 75:3043-3054.
15. Baldwin M.R., Tepp W.H., Przedpelski A., Pier C.L., Bradshaw M., Johnson E.A., et al. Subunit vaccine against the seven serotypes of botulism. Infect Immun 2008, 76:1314-1318.
16. Yu Y.Z., Sun Z.W., Li N., Wang S., Wang R.L., Yu W.Y. Evaluation of a recombinant Hc of Clostridium botulinum neurotoxin serotype F as an effective subunit vaccine. Clin Vaccine Immunol 2008, 15:1819-1823.
17. Stahl C., Unger L., Mazuet C., Popoff M., Straub R., Frey J. Immune response of horses to vaccination with the recombinant Hc domain of botulinum neurotoxin types C and D. Vaccine 2009, 27:5661-5666.
18. Yu Y.Z., Li N., Zhu H.Q., Wang R.L., Du Y., Wang S., et al. The recombinant Hc subunit of Clostridium botulinum neurotoxin serotype A is an effective botulism vaccine candidate. Vaccine 2009, 27:2816-2822.
19. Smith L.A. Development of recombinant vaccines for botulinum toxin. Toxicon 1998, 36:1539-1548.
20. Byrne M.F., Titball R.W., Holley J., Smith L.A. Fermentation, purification, and efficacy of a recombinant vaccine candidate against botulinum neurotoxin type F from Pichia pastoris. Protein Expr Purif 2000, 18:327-337.
21. Boles J., West M., Montgomery V., Tammariello R., Pitt M.L., Gibbs P., et al. Recombinant C fragment of botulinum neurotoxin serotype B (rBoNTB(Hc)) immune response and protection in the rhesus monkey. Toxicon 2006, 47:877-884.
22. Webb R.P., Smith T.J., Wright P.M., Montgomery V.A., Meagher M.M., Smith L.A. Protection with recombinant Clostridium botulinum C1 and D binding domain subunit (Hc) vaccines against C and D neurotoxins. Vaccine 2007, 25:4273-4282.
23. Clayton J., Middlebrook J.L. Vaccination of mice with DNA encoding a large fragment of botulinum neurotoxin serotype A. Vaccine 2000, 18:1855-1862.
24. Shyu R.H., Shaio M.F., Tang S.S., Shyu H.F., Lee C.F., Tsai M.H., et al. DNA vaccination using the fragment C of botulinum neurotoxin type A provided protective immunity in mice. J Biomed Sci 2000, 7:51-57.
25. Bennett A.M., Perkins S.D., Holley J.L. DNA vaccination protects against botulinum neurotoxin type F. Vaccine 2003, 21:3110-3117.
26. Jathoul A.P., Holley J.L., Garmory H.S. Efficacy DNA vaccines expressing the type F botulinum toxin Hc fragment using different promoters. Vaccine 2004, 22:3942-3946.
27. Lee J.S., Pushko P., Parker M.D., Dertzbaugh M.T., Smith L.A., Smith J.F. Candidate vaccine against botulinum neurotoxin serotype A derived from a Venezuelan equine encephalitis virus vector system. Infect Immun 2001, 69:5709-5715.
28. Lee J.S., Groebner J.L., Hadjipanayis A.G., Negley D.L., Schmaljohn A.L., Welkos S.L., et al. Multiagent vaccines vectored by Venezuelan equine encephalitis virus replicon elicits immune responses to Marburg virus and protection against anthrax and botulinum neurotoxin in mice. Vaccine 2006, 24:6886-6892.
29. Yu Y.Z., Zhang S.M., Sun Z.W., Wang S., Yu W.Y. Enhanced immune responses using plasmid DNA replicon vaccine encoding the Hc domain of Clostridium botulinum neurotoxin serotype A. Vaccine 2007, 25:8843-8850.
30. Yu Y.Z., Yu J.Y., Li N., Wang R.L., Wang S., Yu W.Y., et al. Individual and bivalent vaccines against botulinum neurotoxin serotypes A and B using DNA-based Semliki Forest virus vectors. Vaccine 2009, 27:6148-6153.
31. Yu Y.Z., Zhang S.M., Ma Y., Zhu H.Q., Wang W.B., Du Y., et al. Development and evaluation of candidate vaccine and antitoxin against botulinum neurotoxin serotype F. Clin Immunol 2010, 137:271-280.
32. Yu Y.Z., Wang W.B., Li N., Wang S., Yu W.Y., Sun Z.W. Enhanced potency of individual and bivalent DNA replicon vaccines or conventional DNA vaccines by formulation with aluminum phosphate. Biologicals 2011, 38:658-663.
33. Torii Y., Tokumaru Y., Kawaguchi S., Izumi N., Maruyama S., Mukamoto M., et al. Production and immunogenic efficacy of botulinum tetravalent (A, B, E, F) toxoid. Vaccine 2002, 20:2556-2561.
34. Pushko P., Geisbert J., Parker M., Jahrling P., Smith J. Individual and bivalent vaccines based on alphavirus replicons protect guinea pigs against infection with Lassa and Ebola viruses. J Virol 2001, 75:11677-11685.
35. Li N., Yu Y.Z., Yu W.Y., Sun Z.W. Enhancement of the immunogenicity of DNA replicon vaccine of Clostridium botulinum neurotoxin serotype A by GM-CSF gene adjuvant. Immunopharmacol Immunotoxicol 2011, 33:211-219.
36. Hermanson G., Whitlow V., Parker S., Tonsky K., Rusalov D., Ferrari M., et al. A cationic lipid-formulated plasmid DNA vaccine confers sustained antibody-mediated protection against aerosolized anthrax spores. Proc Natl Acad Sci USA 2004, 101:13601-13606.
37. Hirao L.A., Draghia-Akli R., Prigge J.T., Yang M., Satishchandran A., Wu L., et al. Multivalent smallpox DNA vaccine delivered by intradermal electroporation drives protective immunity in nonhuman primates against lethal monkeypox challenge. J Infect Dis 2011, 203:95-102.
38. Merkel T.J., Perera P.Y., Kelly V.K., Verma A., Llewellyn Z.N., Waldmann T.A., et al. Development of a highly efficacious vaccinia-based dual vaccine against smallpox and anthrax, two important bioterror entities. Proc Natl Acad Sci USA 2010, 107:18091-18096.